Genmab AS (GMAB)

Official site

HEALTHCARE • BIOTECHNOLOGY • NASDAQ

$37.82

+0.93 (+2.52%)

Market Cap: $22.68B

Last updated: Oct 16, 2026 at 1:55 PM ET

Earnings

Performance (10Y)

Beat Rate

59%(17/29)

Avg Surprise

+18.08%

Streak

1 Q

Upcoming Estimates

Period ending Sep 30, 2026

EPS Consensus$0.33

Range$0.24 - $0.41

6 analysts

EPS RevisionsNo revisions (7d)

30d

EPS Estimate DriftChange to current

90d ago$0.32+3.4%

60d ago$0.35-6.1%

30d ago$0.34-2.2%

7d ago$0.34-2.2%

Current$0.33

Revenue Consensus

$8.0B

Range$7.7B - $8.3B

11 analysts

Period ending Dec 31, 2026

EPS Consensus$0.30

Range$0.30 - $0.30

1 analysts

Revenue Consensus

$8.8B

Range$7.2B - $10.7B

19 analysts

Period	Reported	Est.	Range	Surprise	B/M	Analysts	Revisions	YoY
Dec 31, 2026Dec 26EST	-	$0.30	$0.30 - $0.30	-	-	1	-	-
Sep 30, 2026Sep 26EST	-	$0.33	$0.24 - $0.41	-	-	6	2 2 30d	-
Jun 30, 2026Jun 26 Reported Aug 6, 2026Reported Aug 6	$0.54	$0.37	$0.29 - $0.49	+45.95%	Beat	4	2 0 30d	+0.0%
Mar 31, 2026Mar 26 Reported May 7, 2026Reported May 7	$0.13	$0.19	$0.16 - $0.19	-31.58%	Miss	2	1 0 30d	-58.1%
Dec 31, 2025Dec 25 Reported Feb 17, 2026Reported Feb 17	$0.21	$0.37	$0.35 - $0.41	-43.24%	Miss	3	1 0 30d	-75.0%
Sep 30, 2025Sep 25 Reported Nov 6, 2025Reported Nov 6	$0.65	$0.45	$0.41 - $0.48	+44.44%	Beat	3	1 0 30d	+124.1%
Jun 30, 2025Jun 25 Reported Aug 7, 2025Reported Aug 7	$0.54	$0.39	$0.39 - $0.39	+38.46%	Beat	1	0 1 30d	+68.8%
Mar 31, 2025Mar 25 Reported May 8, 2025Reported May 8	$0.31	$0.23	$0.23 - $0.23	+34.78%	Beat	1	No revisions (30d)	+6.9%
Dec 31, 2024Dec 24 Reported Feb 12, 2025Reported Feb 12	$0.84	$0.28	$0.27 - $0.51	+200.00%	Beat	5	0 2 30d	+500.0%
Sep 30, 2024Sep 24 Reported Nov 6, 2024Reported Nov 6	$0.29	$0.33	$0.33 - $0.33	-12.12%	Miss	1	No revisions (30d)	-37.0%
Jun 30, 2024Jun 24 Reported Aug 8, 2024Reported Aug 8	$0.32	$0.32	$0.32 - $0.34	+0.00%	Beat	2	2 0 30d	+6.7%
Mar 31, 2024Mar 24 Reported May 2, 2024Reported May 2	$0.29	$0.14	$0.14 - $0.14	+107.14%	Beat	2	2 1 30d	+480.0%
Dec 31, 2023Dec 23 Reported Feb 14, 2024Reported Feb 14	$0.14	N/A	-	-53.33%	Miss	4	1 0 30d	+7.7%
Sep 30, 2023Sep 23 Reported Nov 7, 2023Reported Nov 7	$0.46	$0.31	-	+48.39%	Beat	5	1 0 30d	-13.2%
Jun 30, 2023Jun 23 Reported Aug 3, 2023Reported Aug 3	$0.30	$0.29	-	+3.45%	Beat	4	No revisions (30d)	-25.0%
Mar 31, 2023Mar 23 Reported May 10, 2023Reported May 10	$0.05	N/A	-	-66.67%	Miss	4	No revisions (30d)	-50.0%
Dec 31, 2022Dec 22 Reported Feb 22, 2023Reported Feb 22	$0.13	N/A	-	-60.61%	Miss	5	1 0 30d	-23.5%
Sep 30, 2022Sep 22 Reported Nov 9, 2022Reported Nov 9	$0.53	$0.20	-	+165.00%	Beat	5	No revisions (30d)	+152.4%
Jun 30, 2022Jun 22 Reported Aug 10, 2022Reported Aug 10	$0.40	$0.20	-	+100.00%	Beat	5	No revisions (30d)	+400.0%
Mar 31, 2022Mar 22 Reported May 11, 2022Reported May 11	$0.10	$0.19	-	-47.37%	Miss	-	-	-63.0%
Dec 31, 2021Dec 21 Reported Feb 16, 2022Reported Feb 16	$0.17	N/A	-	-96.79%	Miss	1	No revisions (30d)	+21.4%
Sep 30, 2021Sep 21 Reported Nov 10, 2021Reported Nov 10	$0.21	$0.13	$0.13 - $0.13	+59.70%	Beat	0	0 1 30d	+61.5%
Jun 30, 2021Jun 21 Reported Aug 11, 2021Reported Aug 11	$0.08	$0.07	$0.07 - $0.07	+10.65%	Beat	0	No revisions (30d)	-98.9%
Mar 31, 2021Mar 21 Reported May 5, 2021Reported May 5	$0.27	$0.23	$-0.26 - $0.67	+17.39%	Beat	5	No revisions (30d)	-10.0%
Dec 31, 2020Dec 20 Reported Feb 23, 2021Reported Feb 23	$0.14	N/A	-	-89.06%	Miss	5	1 0 30d	-95.9%
Sep 30, 2020Sep 20 Reported Nov 4, 2020Reported Nov 4	$0.13	N/A	-	-86.87%	Miss	5	1 0 30d	-89.4%
Jun 30, 2020Jun 20 Reported Aug 12, 2020Reported Aug 12	$7.58	$6.43	$0.47 - $8.78	+17.88%	Beat	4	No revisions (30d)	+3690.0%
Mar 31, 2020Mar 20 Reported May 6, 2020Reported May 6	$0.30	$0.29	$0.14 - $0.52	+3.45%	Beat	3	1 0 30d	+1604.5%
Dec 31, 2019Dec 19 Reported Feb 19, 2020Reported Feb 19	$3.41	$3.43	$3.22 - $4.02	-0.58%	Miss	4	3 0 30d	+1568.3%
Sep 30, 2019Sep 19 Reported Nov 6, 2019Reported Nov 6	$1.23	$0.36	$0.36 - $1.22	+241.67%	Beat	3	1 0 30d	+2708.2%
Jun 30, 2019Jun 19 Reported Aug 20, 2019Reported Aug 20	$0.20	$0.27	$0.27 - $0.27	-25.93%	Miss	1	No revisions (30d)	+206.3%
Mar 31, 2019Mar 19 Reported May 8, 2019Reported May 8	$0.02	N/A	-	N/A	Beat	-	-	-65.4%
Dec 31, 2018Dec 18 Reported Mar 31, 2019Reported Mar 31	$0.20	N/A	-	N/A	Beat	-	-	-4.9%
Sep 30, 2018Sep 18 Reported Nov 14, 2018Reported Nov 14	$0.04	N/A	-	N/A	Beat	-	-	+3228.6%
Jun 30, 2018Jun 18 Reported Aug 8, 2018Reported Aug 8	$0.07	N/A	-	N/A	Beat	-	-	-16.4%
Mar 31, 2018Mar 18 Reported Jun 29, 2018Reported Jun 29	$0.05	N/A	-	N/A	Beat	-	-	+1083.7%
Dec 31, 2017Dec 17 Reported Mar 30, 2018Reported Mar 30	$0.21	N/A	-	N/A	Beat	-	-	+476.1%
Sep 30, 2017Sep 17 Reported Nov 8, 2017Reported Nov 8	$-0.00	N/A	-	N/A	Beat	-	-	-
Jun 30, 2017Jun 17 Reported Aug 9, 2017Reported Aug 9	$0.08	N/A	-	N/A	Beat	-	-	-
Mar 31, 2017Mar 17 Reported Jun 29, 2017Reported Jun 29	$0.00	N/A	-	N/A	Beat	-	-	-
Dec 31, 2016Dec 16 Reported Mar 30, 2017Reported Mar 30	$0.04	N/A	-	N/A	Beat	-	-	-

Key Metrics

Valuation
P/E Ratio	24.72	EV/EBITDA	22.12x
Price/FCF	26.91x	FCF Yield	3.72%
Profitability
Profit Margin	19.10%	Operating Margin	35.20%
ROE	14.00%	ROIC	9.21%
Financial Health
Debt/Equity	0.86x	Interest Coverage	4.36x
Current Ratio	2.46x	Quick Ratio	2.44x
Trading Statistics
Beta	0.65	Avg Volume	4.00M
52-Week High	$40.17	52-Week Low	$23.62

Technical Indicators Dashboard

Moving Averages

SMA 10$36.95

SMA 20$36.01

SMA 50$34.17

SMA 200$29.83

EMA 10$36.79

EMA 20$36.05

EMA 50$34.14

EMA 200$30.25

MACD

Line: 0.99Signal: 0.97Hist: 0.03

ADX

ADX: 29.7+DI: 38.5-DI: 20.5

Aroon & PSAR

Aroon Up68.0

Aroon DownN/A

PSAR$34.69

Bollinger Bands

Upper Band$38.48

Lower Band$33.54

%B Position1371%(Upper)

Band Width0.87

RSI (14-Day)

Neutral

62.8

Momentum Oscillators

Stoch %K52.3

Stoch %D51.0

Williams %R-36.5

ROC (10d)9.5%

Momentum3.27

CCI (20d)111.4

MFI (14d)65.0

Volatility Measures

ATR (14d)$1.23(3.3%)

StdDev (20d)1.23

Hist Vol46.5%(High)

Volume Flow

VWAP$37.73

OBV66.3M

AD Line76.8M

CMF (20d)0.099

Volume Metrics

Avg Vol (20d)4.1M

Vol Ratio1.0x

VWMA (20d)$36.33

Pivot Points

R3$38.50

R2$37.87

R1$37.38

Pivot Point$36.75

S1$36.26

S2$35.63

S3$35.14

Advanced Oscillators

TSI23.00

Ultimate Osc55.5

KST89.92

Financial Data

Quarter	Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023	Sep 2023
Total Revenue	$1.16B	$899.32M	$1.05B	$1.02B	$924.81M	$105.23M	$6.44B	$5.54B	$779.00M	$603.00M	$4.68B	$4.71B
Cost of Revenue	$84.00M	$65.24M	$80.76M	$58.00M	$56.99M	$6.18M	$337.00M	$273.00M	$28.00M	$27.00M	$126.00M	$79.00M
Gross Profit	$1.07B	$834.08M	$974.05M	$964.00M	$867.82M	$99.05M	$6.10B	$5.27B	$751.00M	$576.00M	$4.55B	$4.63B

Operating Expenses	$664.00M	$608.24M	$731.79M	$505.00M	$507.89M	$71.38M	$3.94B	$3.17B	$515.00M	$460.00M	$2.88B	$2.95B
R&D	$459.00M	$441.63M	$524.41M	$357.00M	$363.92M	$52.84M	$2.66B	$2.28B	$361.00M	$335.00M	$1.95B	$2.09B
SG&A	$205.00M	$166.00M	$208.00M	$148.00M	$144.00M	$126.00M	$1.25B	$865.00M	$894.00M	$857.00M	$934.00M	$839.00M
Operating Income	$407.00M	$225.83M	$242.27M	$459.00M	$359.92M	$27.67M	$2.16B	$2.10B	$236.00M	$116.00M	$1.67B	$1.69B

Interest Income	$36.00M	$14.00M	$48.00M	$32.00M	$25.00M	$33.00M	$224.00M	$162.00M	$292.00M	$295.00M	$295.00M	$243.00M
Interest Expense	$110.00M	$112.41M	$43.87M	$3.00M	$9.00M	$735,900	$54.00M	$18.00M	$19.00M	$4.00M	$6.00M	$8.00M
Income Before Tax	$295.00M	$74.27M	$54.83M	$482.00M	$422.91M	$35.91M	$3.60B	$1.72B	$307.00M	$249.00M	$926.00M	$2.67B
Income Tax Expense	$-8,000,000	$21.08M	$23.93M	$81.00M	$86.98M	$7.21M	$-243,000,000	$453.00M	$104.00M	$57.00M	$286.00M	$566.00M

Net Income	$303.00M	$53.20M	$30.91M	$401.00M	$335.93M	$28.70M	$3.85B	$1.27B	$203.00M	$192.00M	$640.00M	$2.10B

EBITDA	$431.00M	$186.69M	$98.70M	$503.00M	$447.91M	$38.90M	$2.35B	$2.23B	$324.00M	$266.00M	$990.00M	$2.76B
EBIT	$405.00M	$186.00M	$99.00M	$485.00M	$431.91M	$36.65M	$2.27B	$2.12B	$310.00M	$253.00M	$932.00M	$2.68B

* Some calculated fields are derived from available data when not provided by source

Related GNG Research

No research available

Be the first to write about GMAB

News

HC Wainwright raises target for Genmab stock from USD 40 to USD 50

HC Wainwright has increased its price target for Genmab (DK0010272202) stock from USD 40 to USD 50, maintaining a Buy rating. This upgrade follows strong third-quarter DARZALEX sales of USD 4.24 billion and positive...

ad-hoc-news.de•Oct 15, 2026 6:42 AM ET10/15/26•Bullish

How Investors Are Reacting To Genmab Stock (CPSE:GMAB) Strong Drug Sales And Trial Data

Genmab (CPSE:GMAB) reported strong third-quarter 2026 DARZALEX sales of US$4.239 billion, alongside positive trial data for its oncology programs...

Simply Wall Street•Oct 15, 2026 3:12 AM ET10/15/26•Bullish

How Investors Are Reacting To Genmab Stock (CPSE:GMAB) Strong Drug Sales And Trial Data

Genmab reported strong third-quarter 2026 DARZALEX sales of US$4.239 billion and positive trial data for epcoritamab and rinatabartsesutecan...

Simply Wall Street•Oct 15, 2026 2:42 AM ET10/15/26•Bullish

Genmab Reports $4.24 Billion in Q3 DARZALEX Sales, Earns Royalties From J&J

Genmab reported Q3 worldwide net sales of DARZALEX totaling $4.24 billion. The company earns royalties from Johnson & Johnson (J&J) for sales of DARZALEX. The article notes that a premium subscription is required to read...

Yahoo Finance•Oct 13, 2026 3:39 PM ET10/13/26•Bullish

Physician Views Preview: Can AbbVie and Genmab's Epkinly redefine the first-line treatment of DLBCL?

This article explores whether AbbVie and Genmab's drug Epkinly has the potential to redefine the first-line treatment for Diffuse Large B-cell Lymphoma (DLBCL). The content previews physician views on Epkinly's role...

FirstWord Pharma•Oct 13, 2026 12:06 PM ET10/13/26•Bullish

GMAB Valuation and Fair Value

P/E: 24.7x
Forward P/E: 15.1x
EV/EBITDA: 22.1x
P/FCF: 26.9x
PEG: 4.4x
P/B: 3.9x

See GNG's fair value

GMAB Profitability: Margins, ROIC and FCF

Gross margin: 93.0%
Operating margin: 35.2%
Net margin: 19.1%
ROIC: 9.2%
ROE: 14.0%
FCF margin: 21.0%
FCF yield: 3.7%

GMAB Competitors

Company	Ticker
United Therapeutics Corporation	UTHR
Incyte Corporation	INCY
Koninklijke Philips NV ADR	PHG
Tenet Healthcare Corporation	THC
Roivant Sciences Ltd	ROIV
Insmed Inc	INSM
Quest Diagnostics Incorporated	DGX
STERIS plc	STE

Sector: Healthcare

GMAB Analyst Ratings

Consensus: Buy
Analysts: 11
Strong Buy: 1
Buy: 9
Hold: 1
Sell: 0
Strong Sell: 0

GMAB Bull Case vs Bear Case

Bull case

GMAB converts 21.0% of revenue into free cash flow.
GMAB grew quarterly revenue 24.9% year over year.
90.9% of GMAB's analyst ratings are Buy or Strong Buy.

GMAB Earnings: Beat Rate and Next Report

Beat rate: 5 of 8 quarters (62.5%)
Average surprise: 34.6%
EPS estimate (fiscal period ending Sep 30, 2026): $0.33
Estimate revisions (30 days, fiscal period ending Sep 30, 2026): 2 up, 2 down

Frequently Asked Questions About GMAB

Does GMAB pay dividends?

Genmab AS (GMAB) does not currently pay a regular dividend.

What is GMAB's P/E ratio?

Genmab AS has a price-to-earnings (P/E) ratio of 24.72.

What is GMAB's market cap?

Genmab AS (GMAB) has a market capitalization of $22.68B with a current stock price of $37.82.

Get full access to GNG Research

Create a free account to access portfolio tracking, advanced tools, and more.

Create Free Account Log In

Earnings

Performance (10Y)

Upcoming Estimates

Key Metrics

Technical Indicators Dashboard

Moving Averages

MACD

ADX

Aroon & PSAR

Bollinger Bands

RSI (14-Day)

Momentum Oscillators

Volatility Measures

Volume Flow

Volume Metrics

Pivot Points

Advanced Oscillators

Financial Data

Related GNG Research

News

HC Wainwright raises target for Genmab stock from USD 40 to USD 50

How Investors Are Reacting To Genmab Stock (CPSE:GMAB) Strong Drug Sales And Trial Data

How Investors Are Reacting To Genmab Stock (CPSE:GMAB) Strong Drug Sales And Trial Data

Genmab Reports $4.24 Billion in Q3 DARZALEX Sales, Earns Royalties From J&J

Physician Views Preview: Can AbbVie and Genmab's Epkinly redefine the first-line treatment of DLBCL?

GMAB Valuation and Fair Value

GMAB Profitability: Margins, ROIC and FCF

GMAB Competitors

GMAB Analyst Ratings

GMAB Bull Case vs Bear Case

Bull case

GMAB Earnings: Beat Rate and Next Report

Frequently Asked Questions About GMAB

Related stocks

Get full access to GNG Research